Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity

Anti-Cancer Drugs

Volumn 14, Issue 2, 2003, Pages 175-181

  Ho Lee, Byung ^a   Ock Lee, Chong ^a   Kwon, Myung Ja ^a   Yi, Kyu Yang ^a   Yoo, Sung Eun ^a   Choi, Sang Un ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Cardiovascular adverse effect; KR30031; Multidrug resistance; Paclitaxel; Verapamil

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLYCOPROTEIN P; KR 30031; PACLITAXEL; VERAPAMIL;

ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; HEART LEFT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; HYPOTENSION; ISOLATED HEART; ISOMER; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; AORTA; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ISOMERISM; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS; VASODILATION; VENTRICULAR FUNCTION, LEFT; VERAPAMIL;

EID: 0037331335     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200302000-00012     Document Type: Article

References (20)

1. Campling BG, Young LC, Beer KA, Lam YM, Deeley RG, Cole SP, et al. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 1997; 3:115-122.
2. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, et al. Homology between P-glycoprotein and a bacterial hemolysin transport protein suggests a model for multidrug resistance. Nature 1986; 324: 485-489.
3. Twentyman PR, Wright KA, Wallace HM. Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro. Br J Cancer 1992; 65:335-340.
4. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41:1967-1972.
5. Tsuruo T, Iida H, Tsukageshi S, Sakurai Y. Increased accumulation of veincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982; 42:4730-4733.
6. Cairo MS, Siegel S, Anas N, Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 1989; 49:1063-1066.
7. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I, et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000; 11:1471-1476.
8. Benson AB, Trump DL, Koeller JM, Egorin MI, Olman EA, Witte RS. Phase I study of vinblastine and verapamil given by concurrent i.v. infusion. Cancer Treat Rep 1985; 69:781-795.
9. Ozols RF, Cunnion RE, Klecker Jr RW, Hamilton TC, Ostchaga Y, Parrillo JE, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987; 5:641-647.
10. Satoh K, Yanagisawa T, Taira N. Coronary vasodilator and cardiac effects of optical isomers of verapamil in the dog. J Cardiovasc Pharmacol 1980; 2:309-318.
11. Echizen H, Brecht T, Niedergesass S, Vogelgesang B, Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 1985; 109:210-217.
12. Takahata O, Krolikowski JG, McCallum JB, Lathrop DA, Bosnjak ZI. Effects of the optical isomers of verapamil on electrophysiological properties of the heart in conscious dogs. Eur J Pharmacol 1998; 355:159-166.
13. Mickisch GH, Kossig J, Keilhauer G, Schlick E, Tschada RK, Alken PM. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 1990; 50:3670-3674.
14. Gruber A, Peterson C, Reizenstein P. D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int J Cancer 1988; 41:224-226.
15. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995; 13:1958-1965.
16. Choi SU, Lee BH, Kim KH, Choi EJ, Park SH, Shin HS, et al. Novel multidrug-resistance modulators, KR-30026 and KR-30031, in cancer cells. Anticancer Res 1997; 17:4577-4582.
17. Choi SU, Kim NY, Choi EJ, Kim KH, Lee CO. Establishment of doxorubicin-resistant subline derived from HCT15 human colorectal cancer cells. Arch Pharm Res 1996; 19:342-347.
18. Choi SU, Lee CO, Kim KH, Choi EJ, Park SH, Shin HS, et al. Reversal of multidrug resistance by novel verapamil analogs in cancer cells. Anti-Cancer Drugs 1998; 9:157-165.
19. Lee BH, Shin HS, Lee CO, Park SH, Yoo SE, Yi KY, et al. Effects of KR-30035, a novel multidrug-resistance modulator, on the cardiovascular system of rats in vivo and on the cell cycle of human cancer cells in vitro. Anti-Cancer Drugs 2000; 11;55-61.
20. Iwahashi T, Okochi E, Ono K, Sugawara I, Tsuruo T, Mori S. Establishment of multidrug resistant human colorectal carcinoma HCT-15 cell lines and their properties. Anticancer Res 1991; 11:1309-1312.